The International Journal of Indian Psychology
ISSN 2348-5396 (Online) | ISSN: 2349-3429 (Print)
Volume 11, Issue 3, July- September, 2023
DIP: 18.01.110.20231103, DOI: 10.25215/1103.110
https://www.ijip.in

Research Paper

Microbiome: Human Nutrition and Psychology

Souvik Tewari[1], Lina Sarkar[2], Prathiksa Pramanik[3], Papia Mukherjee[4], Anirban Pattanayak[5], Khan Farhana Mahreen[6]*

ABSTRACT

In modern World, gut microbiome is the expanding research field. Gut microbiome is the assembly of microbes these are present in gut microbiota of human intestinal cells. Human health, Psychology and gut microbiome interrelationship is very much integrated. Psychology and human nutrition are becoming a rapidly increasing medical burden. Gut microbiota is an important section of the gut-brain network, and it meet up with the brain through the microbiota–gut–brain axis. Psychology of gut brain will bring great advancement in psychology. Gut microbiota composition is altered according to age along with dietary diversification. Gut microbiota plays favourable function in the human health, host's mind and behaviour. Mood and emotion are concerned by the gut microbiota. This review article provides some information about the relationship between gut microbiome, human nutrition and psychology.

Keywords: *Anxiety, Brain Function, Diabetes Mellitus, Dysbiosis, Mood*

Gut microbiome is defined as group of microbes which are resided in gut microbiota of human. It has been ensured straightly or concomitantly (arbitrating the functions of diet) in human metabolism **(Clemente *et al.*, 2012; Valdes *et al.*, 2018)**. The relationship among constitution of intestinal gut microbiome & it's stave off capacity of ailments have described elaborately in multiple literature. Not long ago, authors have documented that, function for gut microbiota in impacting distant organ and mucosal or immune justification **(Belkaid & Hand, 2014; Zheng *et al.*, 2020)**. Substantial attempt is fascinated about comprehending the origin of microbiome community fabrication in personage simultaneously upgrades our apprehension of interconnection among intestinal microbiome & host cells.

[1]Assistant Professor, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore, W.B., India.
[2]Assistant Professor, Department of Psychology, Swami Vivekananda University, Barrackpore, W.B., India.
[3]Research scholar, Department of Food and Nutrition, Swami Vivekananda University, Barrackpore, W.B., India.
[4]Assistant Professor, Department of Psychology, Swami Vivekananda University, Barrackpore, W.B., India.
[5]State Aided College Teacher, Department of Physiology, Mahishadal Raj College (West Bengal), India.
[6]Assistant Professor, Department of Nutrition, Indian Institute of Food Science and Technology, Aurangabad, Maharashtra, India.
*Corresponding Author

Received: June 30, 2023; Revision Received: July 21, 2023; Accepted: July 25, 2023

Gut microbiome & Human health

The complication of Autoimmune disease (AIDs) is ascribed to genetic inheritance & environmental component imbalances. Authors have reported that, dysbiosis is interlinked with autoimmune disorders.

Gut microbiome and Rheumatoid arthritis (RA):

It is the autoimmune disorder that leads joint vandalization along with other ecological component complications which are linked to intestinal biasness & generate oral dysbacteriosis & continuation of arthritis symptoms in intestinal cell & alternative approach in intestinal composition & oral dysbacteriosis & continuation as well as symptoms of arthritis amid which the most crucial factors are smoking, infestation along with dietary inhabits **(Guerreiro *et al*., 2018; de Oliveira *et al*., 2017)**.

The configuration of gut microbiome in rheumatoid arthritis person is changed in comparison to healthy person. According to **Wells *et al*., 2020**, rheumatoid arthritis patients are prone to dysbiosis but in healthy person, microbial diversity is present there. It has observed in comparison among healthy professional & rheumatoid arthritis patients.

Wells *et al*. (2020); Donohoe *et al*. (2012) reported that rheumatoid arthritis prone patients have enhanced level of harmful microbe such as *Prevotella copri*. Besides, *Faecalibacterium* is beneficial microbe which is present at lesion range in rheumatoid arthritis patients. Noteworthy, *Collinsella* is present in there at highest range in rheumatoid arthritis prone people **(Chen *et al*., 2016)**.

In vitro study has experimented about, *Collinsella aerofaciens* enhances permeability of gut microbiota & instigate IL-17A pronouncement that is the cytokine associated in the manifestation of rheumatoid arthritis therefore *Collinsella* is prompt arthritogenic bacterial member in intestine of human **(Zhang *et al*., 2015)**.

Prevotella copri and *Collinsella* are bad microbes as they supress gut microbial functions as well as involved in manifestation of rheumatoid arthritis. In modern research field, it is very much emerged about the interconnection among short chain fatty acids (SCFAs) & arthritis. Result has shown that, SCFAs stop the complication of RA **(Chen *et al*., 2016; Maslowski *et al*., 2009)**. Most crucial fatty acid is butyrate which is endogenous histone deacetylase (HDAC) stopping agent & fallen infestation of rheumatoid arthritis **(Wang *et al*., 2009)**. Zonulin is a peptide that hold up penetrability of tight junction at epithelial cells, in monitoring the outset of rheumatoid arthritis in rat along with collagen induced arthritis (CIA) **(Tajik *et al*., 2020)**.

Gut microbiota and Type-I diabetes mellitus:

Intestinal microbiome modification like decreases bacterial heterogenicity that leads the manifestation of Type-I diabetes mellitus **(Kostic *et al*., 2015)**. Knowledge have related to many aspects of gut microbiome that manipulate Type-I diabetes mellitus **(Knip & Siljander, 2016; Paun *et al*., 2017; Needell & Zipris, 2016)**. Antibiotic introduced dysbacteriosis change lipid metabolism of microbial cells and stop the activity of Th-17 & T-reg cells which have conducted to enhance the symptoms of Type-I diabetes mellitus **(Livanos *et al*., 2016)**.

Human trial has also shared that, dysbiosis is closely linked with complication of T-I DM **(Maffeis *et al*., 2016; Mejía-León et al.,2014; Alkanani, et al.,2015; de Goffau et**

al.,2014). The usual out comes from the experiment are enhanced Bactericides, decrease the bacterial population which form SCFAs **(de Goffau *et al*., 2014; de Goffau, *et al*., 2013)**. Specially, *Faecalibacterium prausnitzii* is butyrate generate microbe that is present in low range in children gut microbiome who have diabetes linked autoantibody **(Vatanen *et al*., 2018)**.

In accordance with **Mariño *et al*., 2017**, the advantageous effect of SCFAs in Type-I diabetes mellitus have been illuminated in non-obese diabetic (NOD) rat. For instance, NOD rat's intake special foods therefore secrete acetate & butyrate which gives too much security to stop Type-I diabetes mellitus by immunomodulating efficacy of SCFAs. In Type-I diabetes mellitus rats, enhances penetrability in gut microbiome which leads the evolution of this metabolic disorders & ecological elements which regulate the prevalence of T-I DM. Gut penetrability emerges as a crucial factor in the interlinkage among microbiome & expansion of diabetes. Gut dysbiosis & stinging associate with Type-I diabetes mellitus evolution **(de Goffau *et al*., 2013; Vaarala *et al*.,2008)**.

Gut microbiota and atopic eczema:
The infectious stage of eczema has been accredited to decrease the function of skin barrier, uncontrolled immunity & stop the interconnection among human & good microbial group **(Leung & Guttman-Yassky, 2014)**. Ecological component and fast life movement have been demonstrating to incidentally subscribe pathogenesis of disorders by alternation of gut microbiota **(Ta *et al*., 2020)**.

Pothmann *et al*. (2019); Lee *et al*. (2018) revealed that, microbiota in primary life is linked with age of starting, manifestation & suspension of eczema.

Literature review has revealed that, atopic eczema prone patient's gut microbiome is composed of *Clostridia, Clostridium difficile, Escherichia coli, Staphylococcus aureus* however diminish the range of *Bifidobacteria, Bacteroidetes, Bacteroides* on gut microbiome **(Nylund *et al*., 2015; Abrahamsson *et al*., 2012; Lee *et al*., 2016; Song *et al*., 2016)**.

Presence of *Clostridia, E. coli* are closely interlinked to develop eczema through infestation in eosinophil **(Lee *et al*., 2016)**. Butyrate forming bacteria *Caprococcus eutactu*s are elevated in infants along with atopic eczema presence **(Nylund *et al*., 2015)**. Moreover, study has depicted that, eczema prone patient's faecal sample has low amount of butyrate and propionate concentration therefore promote dysbiosis. Furthermore, *Faecalibacterium prausnitzii* reduces the presence of SCFAs producer like butyrate, propionate **(Song *et al*., 2016)**.

Gut microbiota and irritable bowel syndrome (IBS):
Authors have described that, pain in abdominal region & discomfort ness are symptoms of IBS. The reason is multiple but many healthy gut microbiotas may have function in the intestinal infestation linked with critical symptoms **(Brint *et al*., 2011)**. IBS manifestation is observed when *Firmicutes* like *Ruminococcus, Clostridium, Dorea* is present in lesion range additionally, also beneficial microbes like *Bifidobacterium, Faecalibacterium* are there in decreased concentration **(Rajilić-Stojanović *et al*., 2011)**. Moreover, bad microbials like phylum *Proteobacteria*, *Enterobacteriaceae* grouped microbes like Phylum *Bacteroidetes*, The Enterobacteriaceae group composed of harmful microbes like *Escherichia, Shigella, Campylobacter, salmonella* **(Pittayanon *et al*., 2019)**. Research have also revealed that,

development of final compounds from these harmful microbes creates elementary tract disorders such as diarrhoea, abdominal pain, bloating & so on **(Pittayanon *et al*., 2019)**. *Faecalibacterium prausnitzii* preserve gut microbiome & it is butyrate generator & inflammation supressing microbe **(Lopez-Siles *et al*., 2017)** along with prevents IBS by conciliation of IL-17 pronouncement in mice model **(Zhang *et al*., 2014; Wang *et al*., 2014)**, simultaneously keep gut microbial diversity **(Rivière *et al*., 2016)**. FODMAP (Fermentable oligosaccharide, disaccharides, monosaccharides, and polyols) control the symptoms of IBS. This type of diet enhances gut microbiome arrangement as well as metabolite formation microbially **(Chumpitazi, 2020)**. Authors have incorporated that, contrast in microbial functions & it's essay which differentiate among low FODMAP respondent & non respondent **(Leshem *et al*., 2020)**.

Gut microbiota and Inflammatory Bowel disease (IBD):
Chronic inflammatory reaction & ulceration at colon are main symptoms of IBD which have included disorders like Chron's disease (CD), Ulcerative colitis (UC). In general, IBD is the malfunction of elementary tract due to dysbiosis in intestinal cells **(Lepage *et al*., 2011)**. Reduces *Firmicutes* & enhances *Proteobacteria* generate IBD. However usual outcome of dysbiosis in IBD persons, especially in CD, is the less plenty of Firmicutes present in the family Ruminococcaceae & Lachnospiraceae in opposition to control mice **(Matsuoka & Kanai,2015; Kostic *et al*.,2014; Halfvarson *et al*., 2017)**. This healthy microbial family are much crucial in gut microbiome of human as butyrate forming microbe from human microbiota be in to them. So that, breakdown of these bacterial family members in IBD may be interconnected to biasness such as decreased amount of SCFAs butyrate generating ability of IBD microbiome. According to reports, metabolomics & proteomics CD presence microbiota shows low presentation of genes for SCFAs formation and less in metagenomic reads & protein of essential butyrate former *Faecalibacterium prausnitzii* and *Roseburia sp*. **(Morgan *et al*., 2012)**. Butyrate has extensive therapeutic efficacy in IBD as it provides energy for colonocytes, increases epithelial barrier integrity & stop inflammation. Recent study has reviewed the replacement of this is probiotics, that include the intake of butyrate forming microbes to enhance formation of butyrate **(Miquel *et al*., 2013; Tamanai-Shacoori *et al*., 2017)**. Authors have summarised that, butyrate established bacterial community improve gut microbiome health & diminish the manifestation of IBD.

Gut microbiota and Non-alcoholic fatty liver disorder (NAFLD):
Gut dysbiosis is closely associated with enhanced permeability of intestinal cells & outcome is worsening of epithelial barrier, change of tight junction, translocated bacterial cells because of present endotoxemia these are main caused of liver functions deterioration by the portal vein **(Estes *et al*., 2018; Moreira *et al*., 2012)**.

Research has revealed that, community of *Enterobacteriaceae, Collinsella Escherichia, Dorea* is enhanced as well as fallen down the level of *Caprococcus, Eubacterium, Faecalibacterium, Prevotella* **(Hoyles *et al*., 2011; Boursier *et al*., 2016)**. *Faecalibacterium prausnitzii* is the butyrate creator. It's deficiency is the caused of NAFLD **(Iebba *et al*., 2018; Caussy *et al*., 2019)**. *Collinsella sp.* helps to conversion bile acids to oxo bile acid intervening products that enhances permeability into intestinal cells & along with generate NAFLD **(Doden *et al*., 2018)**. Enhanced intestinal penetrability deliver lipopolysaccharides that activate tissues & infestation; however, substances generate microbially like TMA, Choline & bile acid that influence immunity of host **(Aron-Wisnewsky *et al*., 2013; Brandl & Schnabl, 2017)**.

Human gut health and psychology

The cost of treating mental illnesses and neurological conditions is rising quickly. Even though substantial research has been done, the development of efficient treatments for many disorders is still moving slowly. The current predicament serves as a reminder that humans are superorganisms. Only by considering both the human self and its companion microbiome simultaneously can we gain a deeper understanding of these illnesses. Because of contemporary changes in nutrition, lifestyle, medical care, and other factors that have occurred concurrently with the modern epidemiological transition over the past few centuries, the companion microbiota has undergone enormous change, much more so than human DNA.

Research already done suggests that the gut microbiota is crucial to this change. The gut microbiota is an essential component of the gut-brain network, and it communicates with the brain via the microbiota-gut-brain axis, according to gut-brain psychology. Nearly simultaneously with the development of the gut-brain, brain, and mind is the gut microbiota. The pathophysiology of many mental and neurological illnesses is influenced by the gut microbiota, which also affects a variety of normal mental processes and mental phenomena. Three theories—the gut microbiota hypothesis, the "old friend" concept, and the leaky gut theory—support the promising strategy of targeting the microbiome in treatment for various disorders **(DiBaise *et al*., 2008)**.

The neurological system, endocrine system, and immune system make up the majority of the microbiota-gut-brain axis, which mediates the effects of gut bacteria on the brain and behaviour. Psychiatry, neurology, and psychology will all benefit greatly from gut-brain psychology. Numerous microbiota-improving techniques, such as faecal microbiota transplantation, probiotics, prebiotics, a balanced diet, and a healthy lifestyle, have demonstrated their ability to enhance brain and gut function. In the future, it will be feasible to use the gut microbiota to treat and prevent disorders connected to the brain and mental health **(De la Fuente, 2021)**.

The human gut microbiota does not immediately appear; rather, it develops gradually from simple to complex, tends to stabilise, and then gradually diminishes **(Garcia-Pena *et al*., 2017; Vuong *et al*., 2017)**.

Early in the womb is likely when the foetus first comes into contact with microbes; at this time, the microbiota is mostly influenced by the physiological and psychological state of the mother, her nutrition, her use of medications, and other factors **(Lim *et al*., 2016)**. The delivery method substantially influences the newborn's early microbiome. Lactobacillus, for example, is commonly acquired by healthy babies via the mother's vagina, but neonates born via caesarean section typically acquire Clostridium from the air and the mother's skin **(Penders *et al*., 2006; Bokulich *et al*., 2016; von Mutius, 2017)**.

The following stage of feeding habits controls the microbiome. newborns fed formula milk get more *Enterococcus* and *Enterobacterium*, but breastfed newborns acquire more *Bifidobacterium* and *Lactobacillus* **(Penders *et al*., 2006; Bokulich *et al*., 2016; Kundu *et al*., 2017)**.

Use of antibiotics also slows the development of gut microbiota and decreases the abundance of *Bifidobacterium* and *Bacteroides* **(Penders *et al*., 2006; Bokulich *et al*., 2016; Wampach *et al*., 2017)**.

After then, as people age and their diets alter, their gut microbiome changes. For instance, the age-related decline of the first dominating species, such Bifidobacterium **(Penders *et al*., 2006; Bokulich *et al*., 2016)**. After birth, the newborn microbiota's phylogenetic composition quickly rises, and within three years, it changes towards an adult-like structure **(Yatsunenko *et al*., 2012; Bokulich *et al*., 2016)**. Then, as the phylogenetic composition and diversity continue to change, adolescence's profound alterations have a significant impact on the microbiota's growth **(Kundu *et al*., 2017)**.

Adults' gut microbiota is largely stable, and more than 60% of it, including Bacteroidetes and Actinobacteria, doesn't undergo significant change **(Faith *et al*., 2013; Borre *et al*., 2014)**.

As people age, their gut microbiota becomes less diverse while some opportunistic infections, such particular species of *Clostridium*, become more abundant **(Claesson *et al*., 2011; Kundu *et al*., 2017)**.

The gut microbiome affects how the brain and intellect develop and mature **(Diaz Heijtz *et al*., 2011; Borre *et al*., 2014; Galland, 2014; Mu *et al*., 2016; Manderino *et al*., 2017; Bruce-Keller *et al*., 2018)**. Germ-free (GF) animals display aberrant mental development in addition to structural problems in the brain **(Diaz Heijtz *et al*., 2011; Desbonnet *et al*., 2014; Ogbonnaya *et al*., 2015; Hoban *et al*., 2016; Luczynski *et al*., 2016; Chen *et al*., 2016)**. Both neuroplasticity and myelin plasticity are influenced by the gut microbiota **(Ogbonnaya *et al*., 2015; Hoban *et al*., 2016)**.

Mental problems and brain dysfunction can result from aberrant gut microbiome. Early trauma, parental stress, infections at a young age, antibiotic use, and other risk factors that affect microbiota growth also affect how the brain and mind develop **(O'Mahony *et al*., 2009; Borre *et al*., 2014; Gur *et al*., 2015; Diaz Heijtz, 2016; Lim *et al*., 2016; Slykerman *et al*., 2017)**. Early postnatal life is crucial for the development of the gut-brain, brain, and mind, thus abnormalities in the microbiota at this time could cause permanent harm to the brain and mind **(Borre *et al*., 2014; Bokulich *et al*., 2016)**. This may contribute to the notion that early hardship makes people more vulnerable to mental illnesses **(O'Mahony *et al*., 2009, 2017; Mika *et al*., 2017)**.

The gut microbiota is an essential component of the gut-brain network, and it communicates with the brain via the microbiota-gut-brain axis, according to gut-brain psychology.

Nearly simultaneously with the development of the gut-brain, brain, and mind is the gut microbiota. The pathophysiology of many mental and neurological disorders is influenced by the gut microbiota, which also affects a variety of normal brain processes and mental phenomena **(Liang *et al*., 2018)**.

Luczynski et al. (2016**);** Vuong et al. (2017**)** reported that Despite being often disregarded, the gut microbiota has a substantial impact on the host's cognition and behaviour. The gut microbiota and cognitive processes, particularly memory and learning capacity, are intimately connected **(**Gareau, 2016**;** Manderino *et al*., 2017**)**.

Mood and emotion are affected by the gut microbiota **(**Luczynski *et al*., 2016**;** Cowan *et al*., 2017**;** Hoban *et al*., 2017**;** Vuong *et al*., 2017**)**. Animals raised in germ-free environments exhibit atypical anxiety-like behaviours that might be responsive to microbial treatment

(Luczynski et al., 2016). Infected individuals swiftly develop symptoms of illness, including exhaustion, social withdrawal, decreased appetite, and heightened anxiety-like behaviour **(**Lyte *et al*., 2006**;** Lyte, 2013**;** De Palma *et al*., 2014**;** Gur *et al*., 2015**)**.

Additionally, because their brains are more sensitive to pain signals from the GI tract, many persons with functional GI problems experience pain more intensely than other people do. Pain that already exists may seem worse under stress.

According to research by **Johnson and Foster (2018)**, differences in personality, such as friendliness and neuroticism, were correlated with the makeup and diversity of the gut microbiome.

Johnson and Foster (2018) noted that the variance in social behaviour in the general population as well as the extreme behavioural characteristics associated with autism may be influenced by the gut flora. Since this was a cross-sectional study, future research might profit from specifically examining any behavioural effects that these bacteria might have. This could help guide the creation of fresh treatments for depression and autism.

CONCLUSION

In long time before, authentication from animal and human has been gathering and forecast an interrelationship among functions of gut microbiota and omit complication of chronic disorders. According to literature review, metabolites of bacterial cells are present in any part of human organ which is actively present in functions of gut microbiota. Among metabolites short chain fatty acids are very much crucial to stop the manifestation of disorders. Butyrate generating bacteria decreases autoimmune disorders, stomach-intestinal complications, and other disorders. Therapeutic modification alters gut microbiome diversity. On the other hand, it was also found that mood and emotion are affected by the gut microbiota. Although it is sometimes disregarded, the host's gut microbiota has a substantial impact on their thoughts and behaviours. The gut microbiota and cognitive abilities, particularly memory and learning capacity, are tightly connected.

REFERENCES

Abrahamsson, TR., Jakobsson, HE., Andersson, AF., Björkstén, B., Engstrand, L., Jenmalm, MC. (2012). Low diversity of the gut microbiota in infants with atopic eczema. *J Allergy Clin Immunol.* 129, 434–40. 440.e1–2.

Alkanani, AK., Hara, N., Gottlieb, PA., Ir, D., Robertson, CE., Wagner, BD., et al. (2015). Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes.*Diabetes.* 64,3510–20.

Aron-Wisnewsky, J., Gaborit, B., Dutour, A., Clement, K. (2013). Gut microbiota and nonalcoholic fatty liver disease: new insights. *Clin Microbiol Infect.* 19.

Belkaid, Y., Hand, TW. (2014). Role of the microbiota in immunity and inflammation. *Cell.* 157, 121–41.

Bokulich, N. A., Chung, J., Battaglia, T., Henderson, N., Jay, M., Li, H., et al. (2016). Antibiotics, birth mode, and diet shape microbiome maturation during early life. *Sci. Transl. Med.* 8:343ra382.

Borre, Y. E., O'Keeffe, G. W., Clarke, G., Stanton, C., Dinan, T. G., and Cryan, J. F. (2014). Microbiota and neurodevelopmental windows: implications for brain disorders. *Trends Mol. Med.* 20, 509–518.

Boursier, J., Mueller, O., Barret, M., Machado, M., Fizanne, L., Araujo-Perez, F., et al. (2016). The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology*. 63, 764–75.

Brandl, K., Schnabl, B. (2017). Intestinal microbiota and nonalcoholic steatohepatitis. *Curr Opin Gastroenterol*. 33, 128–33.

Brint, EK., MacSharry, J., Fanning, A., Shanahan, F., Quigley, EMM. (2011). Differential expression of toll-like receptors in patients with irritable bowel syndrome. *Am J Gastroenterol*. 106, 329–36.

Bruce-Keller, A. J., Salbaum, J. M., and Berthoud, H. R. (2018). Harnessing gut microbes for mental health: getting from here to there. *Biol. Psychiatry* 83, 214–223.

Caussy, C., Tripathi, A., Humphrey, G., Bassirian, S., Singh, S., Faulkner, C., et al. (2019). A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. *Nat Commun*. 10, 1406.

Chen, J., Wright, K., Davis, JM., Jeraldo, P., Marietta, EV., Murray, J. et al. (2016). An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. *Genome Med.* 8,43.

Chen, Z., Andreev, D., Oeser, K., Krljanac, B., Hueber, A., Kleyer, A. et al. (2016). Th2 and eosinophil responses suppress inflammatory arthritis. *Nat Commun*. 7,11596.

Chumpitazi, BP. (2020). The gut microbiome as a predictor of low fermentable oligosaccharides disaccharides monosaccharides and polyols diet efficacy in functional bowel disorders. *Curr Opin Gastroenterol.* 36, 147–54.

Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., and de Weerd, H. (2011). Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc. Natl. Acad. Sci. U.S.A.* 108, 4586–4591

Clemente, JC., Ursell, LK., Parfrey, LW., Knight, R. (2012). The impact of the gut microbiota on human health: an integrative view. *Cell*. 148, 1258–70.

Cowan, C. S. M., Hoban, A. E., Ventura-Silva, A. P., Dinan, T. G., Clarke, G., and Cryan, J. F. (2017). Gutsy moves: the amygdala as a critical node in microbiota to brain signaling. *Bioessays* 40:1700172.

de Goffau, MC., Fuentes, S., van den Bogert, B., Honkanen, H., de Vos, WM., Welling, GW., et al. (2014). Aberrant gut microbiota composition at the onset of type 1 diabetes in young children. *Diabetologia*. 57,1569–77.

de Goffau, MC., Luopajärvi, K., Knip, M., Ilonen, J., Ruohtula, T., Härkönen, T., et al.(2013). Fecal microbiota composition differs between children with β-cell autoimmunity and those without. *Diabetes*. 62, 1238–44.

De la Fuente, M. (2021). The role of the microbiota-gut-brain axis in the health and illness condition: a focus on Alzheimer's disease. Journal of Alzheimer's Disease, 81(4), 1345-1360.

de Oliveira, GLV., Leite, AZ., Higuchi, BS., Gonzaga, MI., Mariano, VS (2017). Intestinal dysbiosis and probiotic applications in autoimmune diseases. *Immunology*. 52, 1–12.

De Palma, G., Collins, S. M., Bercik, P., and Verdu, E. F. (2014). The microbiota-gut-brain axis in gastrointestinal disorders: stressed bugs, stressed brain or both? *J. Physiol.* 592(Pt 14), 2989–2997.

Desbonnet, L., Clarke, G., Shanahan, F., Dinan, T. G., and Cryan, J. F. (2014). Microbiota is essential for social development in the mouse. *Mol. Psychiatry* 19, 146–148.

Diaz Heijtz, R. (2016). Fetal, neonatal, and infant microbiome: perturbations and subsequent effects on brain development and behavior. *Semin. Fetal. Neonatal. Med.* 21, 410–417.

Diaz Heijtz, R., Wang, S., Anuar, F., Qian, Y., Bjorkholm, B., Samuelsson, A., et al. (2011). Normal gut microbiota modulates brain development and behavior. *Proc. Natl. Acad. Sci. U.S.A.* 108, 3047–3052.

DiBaise, J. K., Zhang, H., Crowell, M. D., Krajmalnik-Brown, R., Decker, G. A., & Rittmann, B. E. (2008, April). Gut microbiota and its possible relationship with obesity. In Mayo clinic proceedings (Vol. 83, No. 4, pp. 460-469). Elsevier.

Doden, H., Sallam, LA., Devendran, S., Ly, L., Doden, G., Danie,l SL., et al. (2018). Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from bile acid 7α-dehydroxylating human gut bacteria. *Appl Environ Microbiol*. 84.

Donohoe, DR., Wali, A., Brylawski, BP., Bultman, SJ.(2012). Microbial regulation of glucose metabolism and cell-cycle progression in mammalian colonocytes. *PLoS One*.7:e46589.

Estes, C., Razavi, H., Loomba, R., Younossi, Z., Sanyal, AJ. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 67, 123–33.

Faith, J. J., Guruge, J. L., Charbonneau, M., Subramanian, S., Seedorf, H., Goodman, A. L., et al. (2013). The long-term stability of the human gut microbiota. *Science* 341:1237439.

Galland, L. (2014). The gut microbiome and the brain. *J. Med. Food* 17, 1261–1272.

Garcia-Pena, C., Alvarez-Cisneros, T., Quiroz-Baez, R., and Friedland, R. P. (2017). Microbiota and aging. a review and commentary. *Arch. Med. Res.* 48, 681–689.

Gareau, M. G. (2016). Cognitive function and the microbiome. *Int. Rev. Neurobiol.* 131, 227–246.

Guerreiro, CS., Calado, Â., Sousa, J., Fonseca, JE. (2018). Diet microbiota, and gut permeability-the unknown triad in rheumatoid arthritis. *Front Med*. 5, 349.

Gur, T. L., Worly, B. L., and Bailey, M. T. (2015). Stress and the commensal microbiota: importance in parturition and infant neurodevelopment. *Front. Psychiatry* 6:5.

Halfvarson, J., Brislawn, CJ., Lamendella, R., Vázquez-Baeza, Y., Walters, WA., Bramer, LM., et al. (2017). Dynamics of the human gut microbiome in inflammatory bowel disease. *Nat Microbiol*. 2, 17004.

Hoban, A. E., Stilling, R. M., Moloney, G., Shanahan, F., Dinan, T. G., Clarke, G., et al. (2017). The microbiome regulates amygdala-dependent fear recall. *Mol. Psychiatry* 23, 1134–1144.

Hoban, A. E., Stilling, R. M., Ryan, F. J., Shanahan, F., Dinan, T. G., Claesson, M. J., et al. (2016). Regulation of prefrontal cortex myelination by the microbiota. *Transl. Psychiatry* 6:e774.

Hoyles, L., Fernández-Real, J-M., Federici, M., Serino, M., Abbott, J., Charpentier, J., et al. (2018). Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. *Nat Med.* 24, 1070–80.

Iebba, V., Guerrieri, F., Di Gregorio, V., Levrero, M., Gagliardi, A., Santangelo, F., et al. (2018). Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. *Sci Rep*. 8, 8210.

Johnson, K. V. A., & Foster, K. R. (2018). Why does the microbiome affect behaviour?. *Nature reviews microbiology*, *16*(10), 647-655.

Knip, M., Siljander, H. (2016). The role of the intestinal microbiota in type 1 diabetes mellitus. *Nat Rev Endocrinol*. 12, 154–67.

Kostic, AD., Gevers, D., Siljander, H., Vatanen, T., Hyötyläinen, T., Hämäläinen, A-M., et al. (2015). The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. *Cell Host Microbe*. 17, 260–73.

Kostic, AD., Xavier, RJ., Gevers, D. (2014). The microbiome in inflammatory bowel disease: current status and the future ahead. *Gastroenterology*. 146, 1489–99.

Kundu, P., Blacher, E., Elinav, E., and Pettersson, S. (2017). Our gut microbiome: the evolving inner self. *Cell* 171, 1481–1493. doi: 10.1016/j.cell.2017.11.024

Lee, E., Lee, S-Y., Kang, M-J., Kim, K., Won, S., Kim, B-J, et al. (2016). Clostridia in the gut and onset of atopic dermatitis via eosinophilic inflammation. *Ann Allergy Asthma Immunol*. 117, 91–92.e1.

Lee, SY., Lee, E., Park, YM., Hong, SJ. (2018). Microbiome in the gut-skin axis in atopic dermatitis. *Allergy Asthma Immunol Res*. 10, 354–62.

Lepage, P., Häsler, R., Spehlmann, ME., Rehman, A., Zvirbliene, A., Begun, A., et al. (2011). Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. *Gastroenterology*. 141, 227–36.

Leshem, A., Segal, E., Elinav, E. (2020). The gut microbiome and individual-specific responses to diet. *mSystems*.5.

Leung, DYM., Guttman-Yassky, E. (2014). Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. *J Allergy Clin Immunol*. 134, 769–79.

Liang, S., Wu, X., & Jin, F. (2018). Gut-brain psychology: rethinking psychology from the microbiota–gut–brain axis. *Frontiers in integrative neuroscience*, 33.

Lim, E. S., Wang, D., and Holtz, L. R. (2016). The bacterial microbiome and virome milestones of infant development. *Trends Microbiol.* 24, 801–810.

Livanos, AE., Greiner, TU., Vangay, P., Pathmasiri, W., Stewart, D., McRitchie, S. et al. (2016). Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. *Nat Microbiol*. 1, 16140.

Lopez-Siles, M., Duncan, SH., Garcia-Gil, LJ., Martinez-Medina, M. (2017). Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics. *ISME J.* 11, 841–52.

Luczynski, P., McVey Neufeld, K. A., Oriach, C. S., Clarke, G., Dinan, T. G., and Cryan, J. F. (2016). Growing up in a bubble: using germ-free animals to assess the influence of the gut microbiota on brain and behavior. *Int. J. Neuropsychopharmacol.* 19:pyw020.

Lyte, M. (2013). Microbial endocrinology in the microbiome-gut-brain axis: how bacterial production and utilization of neurochemicals influence behavior. *Plos Pathog.* 9:e1003726.

Lyte, M., Li, W., Opitz, N., Gaykema, R. P., and Goehler, L. E. (2006). Induction of anxiety-like behavior in mice during the initial stages of infection with the agent of murine colonic hyperplasia *Citrobacter rodentium*. *Physiol. Behav.* 89, 350–357.

Maffeis, C., Martina, A., Corradi, M., Quarella, S., Nori, N., Torriani, S. et al. (2016). Association between intestinal permeability and faecal microbiota composition in Italian children with beta cell autoimmunity at risk for type 1 diabetes. *Diabetes Metab Res Rev*. 32,700–9.

Manderino, L., Carroll, I., Azcarate-Peril, M. A., Rochette, A., Heinberg, L., Peat, C., et al. (2017). Preliminary evidence for an association between the composition of the gut microbiome and cognitive function in neurologically healthy older adults. *J. Int. Neuropsychol. Soc.* 23, 700–705.

Mariño, E., Richards, JL., McLeod, KH., Stanley D., Yap, YA., Knight, J., et al. (2017). Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. *Nat Immunol*. 18, 552–62.

Maslowski, KM., Vieira, AT., Ng, A., Kranich, J., Sierro, F., Yu, D. et al. (2009). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. *Nature.* 461,1282–6.

Matsuoka, K., Kanai, T. (2015). The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 37, 47–55.

Mejía-León, ME., Petrosino, JF., Ajami, NJ., Domínguez-Bello, MG., de la Barca, AMC. (2014). Fecal microbiota imbalance in Mexican children with type 1 diabetes. *Sci Rep*. 4, 3814.

Mika, A., Day, H. E., Martinez, A., Rumian, N. L., Greenwood, B. N., Chichlowski, M., et al. (2017). Early life diets with prebiotics and bioactive milk fractions attenuate the impact

of stress on learned helplessness behaviours and alter gene expression within neural circuits important for stress resistance. *Eur. J. Neurosci.* 45, 342–357.

Miquel, S., Martín, R., Rossi, O., Bermúdez-Humarán, LG., Chatel, JM., Sokol, H., et al. (2013). Faecalibacterium prausnitzii and human intestinal health. *Curr Opin Microbiol*. 16,255–61.

Moreira, APB., Texeira, TFS., Ferreira, AB., Peluzio, M., do, CG., Alfenas, R., de, CG. (2012). Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. *Br J Nutr*. 108, 801–9.

Morgan, XC., Tickle, TL., Sokol, H., Gevers, D., Devaney, KL., Ward, DV., et al. (2012). Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome Biol*.13, R79.

Mu, C., Yang, Y., and Zhu, W. (2016). Gut microbiota: the brain peacekeeper. *Front. Microbiol.* 7:345.

Needell, JC., Zipris, D. (2016). The role of the intestinal microbiome in type 1 diabetes pathogenesis. *Curr Diab Rep*.16,89.

Nylund, L., Nermes, M., Isolauri, E., Salminen, S., de Vos, WM., Satokari, R. (2015). Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. *Allergy*. 70, 241–4.

O'Mahony, S. M., Marchesi, J. R., Scully, P., Codling, C., Ceolho, A. M., Quigley, E. M. M., et al. (2009). Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. *Biol. Psychiatry* 65, 263–267.

Ogbonnaya, E. S., Clarke, G., Shanahan, F., Dinan, T. G., Cryan, J. F., and O'Leary, O. F. (2015). Adult hippocampal neurogenesis is regulated by the microbiome. *Biol. Psychiatry* 78, e7–e9.

Paun, A., Yau, C., Danska, JS. (2017). The influence of the microbiome on type 1 diabetes. *J Immunol*. 198, 590–5.

Penders, J., Thijs, C., Vink, C., Stelma, F. F., Snijders, B., Kummeling, I., et al. (2006). Factors influencing the composition of the intestinal microbiota in early infancy. *Pediatrics* 118, 511–521.

Pittayanon, R., Lau, JT., Yuan, Y., Leontiadis, GI., Tse, F., Surette, M., et al. (2019). Gut microbiota in patients with irritable bowel syndrome-a systematic review. *Gastroenterology*. 157, 97–108.

Pothmann, A., Illing, T., Wiegand, C., Hartmann, AA., Elsner, P. (2019). The microbiome and atopic dermatitis: a review. *Am J Clin Dermatol*. 20, 749–61.

Rajilić-Stojanović, M., Biagi, E., Heilig, HGHJ., Kajander, K., Kekkonen, RA., Tims, S. et al. (2011). Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. *Gastroenterology.*,141: 1792–801.

Rivière, A., Selak, M., Lantin, D., Leroy, F., De Vuyst, L. (2016). Bifidobacteria and butyrateproducing colon bacteria: importance and strategies for their stimulation in the human gut. *Front Microbiol*. 7, 979.

Slykerman, R. F., Thompson, J., Waldie, K. E., Murphy, R., Wall, C., and Mitchell, E. A. (2017). Antibiotics in the first year of life and subsequent neurocognitive outcomes. *Acta Paediatr*. 106, 87–94.

Song, H., Yoo, Y., Hwang, J., Na, Y-C., Kim, HS. (2016). Faecalibacterium prausnitzii subspecies-level dysbiosis in the human gut microbiome underlying atopic dermatitis. *J Allergy Clin Immunol*. 137, 852–60.

Ta, LDH., Chan, JCY., Yap, GC., Purbojati, RW., Drautz-Moses, DI., Koh, YM., et al. (2020). A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema. *Gut Microbes.* 12, 1–22.

Tajik, N., Frech, M., Schulz, O., Schälter, F., Lucas, S., Azizov, V., et al. (2020). Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. *Nat Commun*. 11, 1995.

Tamanai-Shacoori, Z., Smida, I., Bousarghin, L., Loreal, O., Meuric, V., Fong, SB., et al. (2017). Roseburia spp.: a marker of health? *Future Microbiol*. 12,157–70.

Vaarala, O., Atkinson, MA., Neu, J. (2008). The 'perfect storm' for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. *Diabetes.* 57, 2555–62.

Valdes, AM., Walter, J., Segal, E., Spector, TD. (2018). Role of the gut microbiota in nutrition and health. *BMJ*. 361, k2179.

Vatanen, T., Franzosa, EA., Schwager, R., Tripathi, S., Arthur, TD., Vehik, K., et al. (2018). The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. *Nature*. 562, 589–94.

von Mutius, E. (2017). The shape of the microbiome in early life. *Nat. Med.* 23, 274–275.

Vuong, H. E., Yano, J. M., Fung, T. C., and Hsiao, E. Y. (2017). The microbiome and host behavior. *Ann. Rev. Neurosci.* 40, 21–49. doi: 10.1146/annurev-neuro-072116-031347.

Wampach, L., Heintz-Buschart, A., Hogan, A., Muller, E. E. L., Narayanasamy, S., Laczny, C. C., et al. (2017). Colonization and succession within the human gut microbiome by archaea, bacteria, and microeukaryotes during the first year of life. *Front. Microbiol.* 8:738.

Wang, H., Gong, J., Wang, W., Long, Y., Fu, X., Fu, Y., et al. (2014). Are there any different effects of bifidobacterium, lactobacillus and streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? *PLoS One*. 9, e90153.

Wang, L., de Zoeten, EF., Greene, MI., Hancock, WW. (2009). Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. *Nat Rev Drug Disco*. 8, 969–81.

Wells, PM., Adebayo, AS., Bowyer, RCE., Freidin, MB., Finckh, A., Strowig, T, et al. (2020). Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study. *Lancet Rheumatol*. 2, e418–e427.

Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., et al. (2012). Human gut microbiome viewed across age and geography. *Nature* 486, 222–227.

Zhang, M., Qiu, X., Zhang, H., Yang, X., Hong, N., Yang, Y., et al. (2014). Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. *PLoS One.* 9, e109146.

Zhang, X., Zhang, D., Jia, H., Feng, Q., Wang, D., Liang, D, et al. (2015). The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. *Nat Med*. 21,895–905.

Zheng, D., Liwinski, T., Elinav, E. (2020). Interaction between microbiota and immunity in health and disease. *Cell Res*. 30, 492–506.

Acknowledgement

The author(s) appreciates all those who participated in the study and helped to facilitate the research process.

Conflict of Interest

The author(s) declared no conflict of interest.

How to cite this article: Tewari, S., Sarkar, L., Pramanik, P., Mukherjee, M., Pattanayak, A. & Khan, F.M. (2023). Microbiome: Human Nutrition and Psychology. *International Journal of Indian Psychology, 11(3),* 1146-1157. DIP:18.01.110.20231103, DOI:10.25215/1103.110